Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

There are hundreds of conditions that have itch as an underlying symptom, according to Brian S. Kim, MD, MTR, the Sol and ...

Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options ...

Septerna, Inc. ( (SEPN) ) just unveiled an announcement.

Septerna (NASDAQ:SEPN – Get Free Report) is projected to announce its Q1 2025 earnings results on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.38) per share for ...

About Septerna Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform.

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform.

Septerna anticipates initiating a Phase 1 clinical trial to assess safety, tolerability, PK, and pharmacodynamics (through an icatibant skin challenge) of SEP-631 in healthy volunteers in the third ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 diabetes, obesity and other cardiometabolic diseases. The exclusive global ...

Septerna continues to advance multiple lead compounds with distinct chemical structures unrelated to its first-generation oral small molecule, SEP-786, each with favorable pharmacokinetics (PK ...

Septerna continues to progress several TSHR NAM lead compounds, designed to be a disease-modifying treatment for Graves' disease and thyroid eye disease, towards selection of a development candidate.

--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...